The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19

被引：0

作者：

Azimi, Saeid ^{[1
]}

Saghafi, Fatemeh ^{[2
]}

Mohammadi, Mohammad Hossein ^{[3
]}

Moghimi, Mohammad Hossein ^{[4
]}

Akhavan, Seyed Ali ^{[4
]}

Khataminia, Masoud ^{[5
]}

Shirvani, Maria ^{[6
]}

Sohrevardi, Seyed Mojtaba ^{[2
]}

Jamialahmadi, Tannaz ^{[7
]}

Sahebnasagh, Adeleh ^{[8
]}

Sahebkar, Amirhossein ^{[7
,9
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Student Res Comm, Fac Pharm, Tehran, Iran

[2] Shahid Sadoughi Univ Med Sci, Fac Pharm & Pharmaceut Sci, Res Ctr, Dept Clin Pharm, Yazd, Iran

[3] Shahid Sadoughi Univ Med Sci, Yazd, Iran

[4] Shahid Sadoughi Univ Med Sci, Student Res Comm, Fac Pharm, Yazd, Iran

[5] Univ Tehran Med Sci, Student Res Comm, Fac Pharm, Tehran, Iran

[6] Kermanshah Univ Med Sci, Imam Reza Hosp, Clin Res Dev Ctr, Kermanshah, Iran

[7] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran

[8] North Khorasan Univ Med Sci, Dept Internal Med, Clin Res Ctr, Bojnurd, Iran

[9] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran

来源：

CURRENT PHARMACEUTICAL DESIGN | 2023年 / 29卷 / 29期

关键词：

COVID-19; acute respiratory distress syndrome; cytokine; survival rate; immunosuppressant; cannabidiol; DOMAIN-LIKE RECEPTORS; CBD; PATHOGENESIS; INFLAMMATION; SYMPTOMS;

D O I：

10.2174/0113816128275803230920094909

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

COVID-19 disease manifests itself in a wide range of signs and symptoms, beginning with mild symptoms, such as fever, cough, and dyspnea, progressing to acute respiratory distress syndrome (ARDS) and death in some cases. The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 patients, early management of the cytokine storm with immunomodulators is crucial. Although the effectiveness of some immunosuppressants, such as corticosteroids and tocilizumab, has been studied in clinical trials, the administration of these drugs should be exercised cautiously. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid from Cannabis sativa extracts with anti-inflammatory properties. This review is intended to discuss the possible utility of CBD for the management of COVID-19 patients, particularly those with ARDS.

引用

页码：2291 / 2296

页数：6

共 66 条

[1] Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies [J].

Abassi, Zaid A. ;

Skorecki, Karl ;

Heyman, Samuel Noam ;

Kinaneh, Safa ;

Armaly, Zaher .

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2020, 318 (05) :L1020-L1022

[2] Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise Endurance in Advanced Chronic Obstructive Pulmonary Disease A Randomized Controlled Trial [J].

Abdallah, Sara J. ;

Smith, Benjamin M. ;

Ware, Mark A. ;

Moore, Michelle ;

Li, Pei Zhi ;

Bourbeau, Jean ;

Jensen, Dennis .

ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (10) :1146-1158

[3]

[Anonymous], 2020, CDC strategy for global response to COVID- 19 (2020-2023)

[4] Cannabidiol reduces lung injury induced by hypoxic-ischemic brain damage in newborn piglets [J].

Arruza, Luis ;

Ruth Pazos, Maria ;

Mohammed, Nagat ;

Escribano, Natalia ;

Lafuente, Hector ;

Santos, Martin ;

Alvarez-Diaz, Francisco J. ;

Hind, William ;

Martinez-Orgado, Jose .

PEDIATRIC RESEARCH, 2017, 82 (01) :79-86

[5] Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019 [J].

Bifulco, Maurizio ;

Fiore, Donatella ;

Piscopo, Chiara ;

Gazzerro, Patrizia ;

Proto, Maria Chiara .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[6] The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial [J].

Boggs, Douglas L. ;

Surti, Toral ;

Gupta, Aarti ;

Gupta, Swapnil ;

Niciu, Mark ;

Pittman, Brian ;

Martin, Ashley M. Schnakenberg ;

Thurnauer, Halle ;

Davies, Andrew ;

D'Souza, Deepak C. ;

Ranganathan, Mohini .

PSYCHOPHARMACOLOGY, 2018, 235 (07) :1923-1932

[7] Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis [J].

Booth, Adam ;

Reed, Angus Bruno ;

Ponzo, Sonia ;

Yassaee, Arrash ;

Aral, Mert ;

Plans, David ;

Labrique, Alain ;

Mohan, Diwakar .

PLOS ONE, 2021, 16 (03)

[8] Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis [J].

Borrelli, Francesca ;

Aviello, Gabriella ;

Romano, Barbara ;

Orlando, Pierangelo ;

Capasso, Raffaele ;

Maiello, Francesco ;

Guadagno, Federico ;

Petrosino, Stefania ;

Capasso, Francesco ;

Di Marzo, Vincenzo ;

Izzo, Angelo A. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2009, 87 (11) :1111-1121

[9] Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use [J].

Brown, Joshua D. ;

Winterstein, Almut G. .

JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)

[10] Cannabidiol (CBD) and its analogs: a review of their effects on inflammation [J].

Burstein, Sumner .

BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (07) :1377-1385

← 1 2 3 4 5 6 7 →